

## Pharmacy Request for Prior Approval – Hetlioz and Hetlioz LQ

Beneficiary Information					
1. Beneficiary Last Name:	2.				
3. Beneficiary ID #:	4. Beneficiary Date of Birth:		5. Beneficiary Gender:		
Prescriber Information					
6. Prescriber Name:	NPI #:				
Mailing address:			State:		ZIP:
7. Requester Contact Information:					
Name:	Phone #:		Fax #:		
Drug Information					
8. Drug Name:	9. Strength:		10. Quantity Per 30 Days:		
11. Length of Therapy: Initial Request:up to	o 30 days60 days90 day	S			
Reauthorization Reque	st:up to 30 days60 days	90 days _	120 days	180 days	
Clinical Information					
Initial Request for Hetlioz – Non-24 Sleep-Wake Disorder: (answer questions 1-5)					
1. Is the beneficiary at least 18 years old or older? Yes No					
2. Does the beneficiary have a documented diagnosis of Non-24 sleep-wake disorder? Yes No					
3. The diagnosis of Non-24 sleep-wake disorder is confirmed by meeting ONE of the following conditions:					
Assessment of at least one physiologic circadian phase marker (e.g., measurement of urinary melatonin levels, dim light					
melatonin onset [as measured in blood or saliva], assessment of core body temperature.)					
If the assessment of at least one physiologic circadian phase marker cannot be done, the diagnosis must be confirmed by					
actigraphy performed for >/= 1 week plus evaluation of sleep logs recorded for >/= 1 month.					
4. Has the beneficiary had an insufficient response or intolerance to at least two (2) other medications, over-the-counter or prescription,					
for sleep? Yes No					
5. Is this medication being prescribed by, or is the physician consulting with, a physician who specialized in the treatment of sleep					
disorders? Yes No					
Initial Request for Hetlioz – Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS): (answer questions 6-10)					
6. Is the beneficiary at least 16 years of age or older? Yes No					
7. Does the beneficiary have a documented diagnosis of Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)?					
Yes No					
8. Has the beneficiary had an insufficient response or intolerance to at least two (2) other medications, over-the-counter or prescription,					
for sleep? Yes No					
10. Is this medication being prescribed by, or is the physician consulting with, a physician who specialized in the treatment of sleep					
disorders? Yes No					
Initial Request for Hetlioz LQ – Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS): (answer questions 11-14)					
11. Is the beneficiary between 3 years and 15 years of age? Yes No					
12. Does the beneficiary have a documented di	agnosis of Nighttime sleep dist	urbances in Sr	mith-Magenis S	Syndrome (SM	1S)?
Yes No			_		
13. Has the beneficiary had an insufficient resp	onse or intolerance to at least t	wo (2) other r	medications, o	ver-the-count	er or
prescription, for sleep? Yes No					
14. Is this medication being prescribed by, or is	the physician consulting with,	a physician wh	no specialized i	in the treatme	ent of sleep
disorders? Yes No					
Re-authorization for Treatment: (answer ques	tions 15 & 16 below)				
15. Has the beneficiary used Hetlioz or Hetlioz LQ continuously without gaps in treatment for the initial approval period of three (3)					
months? Yes No					
16. As the provider, have you included an objective evaluation of the beneficiary's sleep quality, including documentation of an					
improvement in overall sleep quality while taking Hetlioz/Hetlioz LQ? Yes No					
**Documentation of the beneficiary's overall sleep quality improvement must accompany this reauthorization for Hetlioz and Hetlioz LQ.**					
· · · · · · · · · · · · · · · · · · ·		-			
Signature of Prescriber:	Da	te:			

\*Prescriber signature mandatory

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.